Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Clinical trial NCT06463171 · UNKNOWN

Trial details

NCT number: NCT06463171
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer Non-small Cell Stage IV

Start date: 2024-06-01
Primary completion: 2026-06-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.